Physician profile
Christopher J Huffer
NPI 1932234325
$2,220.55
in general payments reported to CMS, 2019-2025
37 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $18.69 · 2021: $115 · 2022: $223 · 2023: $316 · 2024: $240 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.82 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $830.00 | 2019 | |
| Glaxosmithkline, LLC. | $215.02 | 2021-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $122.39 | 2022-2025 | |
| Mylan Specialty L.P. | $100.99 | 2021-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $78.95 | 2019 | |
| Insmed, INC. | $70.44 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $66.51 | 2024 | Dupixent |
| Ucb, INC. | $56.19 | 2021-2025 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $48.23 | 2025 | Eohilia, Glassia |
| Cardiovascular Systems INC. | $44.02 | 2022 | |
| Inspire Medical Systems, INC. | $40.92 | 2023 | Inspire |
| Harmony Biosciences LLC | $39.35 | 2025 | |
| Neurocrine Biosciences, INC. | $38.80 | 2024-2025 | Ingrezza |
| Kyowa Kirin, INC. | $27.69 | 2023 | Crysvita |
| Argenx US, INC. | $27.22 | 2025 | Vyvgart |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.37 | 2023 | Quviviq |
| Janssen Biotech, INC. | $24.44 | 2021 | |
| Grifols USA, LLC | $23.68 | 2024 | Prolastin-C Liquid |
| Alkermes, INC. | $22.45 | 2024 | Vivitrol |
| Averitas Pharma INC. | $21.37 | 2023 | Qutenza |
| Aimmune Therapeutics, INC. | $20.79 | 2025 | Vowst |
| Lilly USA, LLC | $20.69 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $19.82 | 2024 | (Ak6) Vest Therapy |
| Boston Scientific Corporation | $19.62 | 2019 | |
| Electromed, INC. | $19.16 | 2025 | Smartvest |
| Resmed Corp | $18.69 | 2020 | |
| Axsome Therapeutics, INC. | $18.25 | 2023 | Sunosi |
| Exact Sciences Corporation | $17.41 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $16.89 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.20 | 2019 | |
| Amgen INC. | $15.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.42 | 2019 | |
| Pulmonx Corporation | $14.04 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Paratek Pharmaceuticals, INC. | $13.97 | 2024 | Nuzyra |
| Pfizer INC. | $11.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Huffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.